Fenton Whelan Limited, et al. v. Cleveland Clinic Foundation, et al.

CourtDistrict Court, N.D. Ohio
DecidedOctober 27, 2025
Docket1:25-cv-00275
StatusUnknown

This text of Fenton Whelan Limited, et al. v. Cleveland Clinic Foundation, et al. (Fenton Whelan Limited, et al. v. Cleveland Clinic Foundation, et al.) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fenton Whelan Limited, et al. v. Cleveland Clinic Foundation, et al., (N.D. Ohio 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO

Fenton Whelan Limited, et al., Case No. 1:25-cv-00275-PAB

Plaintiffs,

-vs- JUDGE PAMELA A. BARKER

Cleveland Clinic Foundation, et al.

Defendants. MEMORANDUM OPINION & ORDER

Currently pending before the Court is Defendants The Cleveland Clinic Foundation (“CCF”), William Peacock, Dennis Laraway, and Jorge “Pat” Rios’ (collectively, “Defendants”) Motion to Dismiss Plaintiff’s Amended Complaint on Forum Non Conveniens Grounds (the “Motion to Dismiss”). (Doc. No. 19.) Plaintiffs Fenton Whelan Limited (“Fenton”) and 21 GP Limited (“21 GP”) filed a Brief in Opposition to Defendants’ Motion to Dismiss on May 7, 2025, to which Defendants replied on May 21, 2025. (Doc. Nos. 19, 25.) Also pending is Plaintiffs’ Motion for Leave to File a Sur-Reply (the “Motion for Leave”). (Doc. No. 26.) Defendants filed a Response to the Motion for Leave on May 30, 2025. (Doc. No. 28.) For the reasons set forth herein, Plaintiffs’ Motion for Leave (Doc. No. 26) and Defendants’ Motion to Dismiss (Doc. No. 19) are GRANTED as set forth herein. The proposed Sur-Reply attached to the Motion for Leave is deemed filed as of May 29, 2025. Plaintiffs’ Amended Complaint is dismissed without prejudice. Dismissal is conditioned upon the following terms: (1) Defendants shall consent to, and shall not challenge, service and jurisdiction in England; (2) in the English proceeding, Defendants shall produce to Plaintiffs any evidence in their possession, custody, or control that is located in the United States and is discoverable under English law; and (3) in the English proceeding, Defendants shall, at their cost, make their employees that are relevant to this dispute, as determined by English law, available to testify at trial or at any other applicable proceeding. Plaintiffs shall have the right to refile this action if Defendants fail to abide by the preceding conditions or if the English court determines that it lacks jurisdiction over Defendants regarding this dispute. I. Relevant Factual Allegations in the Amended Complaint A. The parties enter into negotiations for the acquisition of certain property in London, England Plaintiffs are English entities. (Doc. No. 11 at ¶ 14–15.) Fenton is a “property development and design business” based in London. (Id. at ¶¶ 14, 28.) 21 GP is Fenton’s subsidiary and was formed to develop the property at issue in this lawsuit (the “Property”). (Id. at ¶ 15.) Defendant CCF is based in Cleveland, and Defendants Laraway (CCF’s CFO), Peacock (CCF’s CEO), and Rios (CCF’s Global Head of Real Estate and Construction) reside in Cleveland. (Id.at ¶¶ 17–20.) The

Property is located at 21-24 Grosvenor Place in London, England and “is next door to the Cleveland Clinic London Hospital.” (Id. at ¶ 2.) The Property was initially owned by non-party MeAg Munich ERGO (“MeAg”). (Id. at ¶ 3.) In the spring of 2023, Fenton entered into negotiations with Defendant CCF and non-party Cleveland Clinic London Ltd. (“CCL”) for Fenton to jointly develop a cancer center at the Property (hereinafter “the Project”). (Id. at ¶¶ 2, 32.) “The general framework of the transaction was for Fenton to purchase and develop the Property, which CCL would lease and occupy.” (Id. at ¶ 2.) CCL is a subsidiary of CCF. (Id. at ¶ 2.) On September 15, 2023, 21 GP and CCL “signed Heads of Terms, which contained detailed terms relating to the purchase and development of the Property.” (Id. at ¶ 40.) During the negotiations, Defendant Laraway, Chief Financial Officer of CCF, and non-

2 party Dr. Tomislav Mihaljevic, CCF’s global CEO, visited London and toured the Property. (Id. at ¶¶ 19, 38, 41.) In December 2023, “despite months of negotiations, CCL and CCF unexpectedly withdrew from discussions regarding the purchase and development of the Property.” (Id. at ¶ 44.) Plaintiffs allege that CCF and CCL “approached MeAg directly about buying and developing the Property without Fenton.” (Id. at ¶ 45.) Plaintiffs further allege that “[b]y cutting Fenton out of the project,

and working with MeAg directly, [CCF and CCL] attempted to leverage and reap the benefits of the substantial investment and contributions that Fenton had already made to the Project, leaving Fenton with nothing.” (Id. at ¶ 46) CCF and CCL, however, were “unable to complete a deal for the purchase of the Property with MeAg.” (Id.) B. 21 GP enters into an agreement to purchase the Property “[R]ecognizing the Property’s extraordinary value proposition,” Fenton entered into discussions with MeAg regarding the purchase of the Property. (Id. at ¶¶ 30, 47.) 21 GP entered into a purchase agreement with MeAg (the “MeAg Agreement”) in December 2023. (Id. at ¶ 48.) Under the MeAg Agreement, 21 GP agreed to purchase the Property for the price of £61,610,600 (approximately $78 million) by May 15, 2024 and paid a non-refundable deposit of £6,161,060 (approximately $7.8 million) to secure the Property. (Id.) Under the terms of the MeAg Agreement,

if 21 GP failed to fund the Property purchase by May 15, 2024, 21 GP would be in breach of the Agreement and lose its $7.8 million deposit “and all other money and resources expended on the Project, as well as its anticipated profits.” (Id. at ¶ 49.) C. The parties’ negotiations resume “After learning that 21 GP had entered into the MeAg Agreement,” CCF and CCL “asked to re-start discussions with Fenton regarding the purchase and development of the Property.” (Id. at ¶ 3 51.) An in-person meeting was held on around January 19, 2024 in CCL’s London offices, during which CCF and CCL representatives “informed Fenton of [CCF’s] extraordinary ethical standards” and expressed that “frank and honest communication between Fenton and [CCF and CCL] with respect to the Project was essential.” (Id. at ¶ 52.) In attendance were representatives of CCF and CCL. (Id.) At the meeting “representatives from [CCF] insisted that representatives from Fenton travel to Ohio to meet with [CCF’s] U.S. executive leadership team.” (Id. at ¶ 53.) CCF and CCL

“made it clear that it would engage in discussions if Fenton agreed to meet with [CCF’s] executive leadership in Cleveland, Ohio.” (Id.) On February 21, 2024, Fenton representatives Sanjay Sharma and James Van Den Heule met with Defendants Laraway, Peacock, and Rios at CCF’s home offices in Cleveland. (Id. at ¶ 55.) After this visit, the parties participated in numerous calls and design team meetings, conducted site visits, and continued to negotiate terms prior to the May 15, 2024 deadline in the MeAg Agreement. (Id. at ¶¶ 56–86.) During this time period, Plaintiffs repeatedly and explicitly stated to Defendants that Plaintiffs needed CCF to commit to the Project by mid-March 2024, in light of the May 15, 2024 funding deadline. (Id. at ¶¶ 56, 57, 60, 64.) As of March 11, 2024, CCF and CCL “had not fully committed to the Project.” (Id. at ¶ 60.) On March 18, 2024, CCL’s CFO (Michael Herb) met with

Fenton at Fenton’s offices. (Id. at ¶ 62.) At that meeting, Mr. Herb indicated that CCL and CCF were “looking at other properties in London,” but “that he considered the other properties to be backup only” and “was committed to move forward with developing [the] cancer center at the Property.” (Id. at ¶ 63.)

4 D. The parties’ negotiations cease On April 25, 2024 (the day after an extensive design team call and the day before a scheduled final drafting session), “Defendants Peacock and Rios scheduled a video conference with Mr. Sharma, on just a few hours’ notice.” (Id. at ¶ 87.) “During that call, which lasted approximately five minutes, Defendants Peacock and Rios informed Mr. Sharma that CCF’s executive leadership had decided to not proceed with the transaction.” (Id. at ¶ 88.) “Defendants Peacock and Rios did not provide any reason for the Foundation’s sudden decision to terminate the project, and refused to discuss

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gulf Oil Corp. v. Gilbert
330 U.S. 501 (Supreme Court, 1947)
Piper Aircraft Co. v. Reyno
454 U.S. 235 (Supreme Court, 1982)
Steven Thomas Dowling v. Richardson-Merrell, Inc.
727 F.2d 608 (Sixth Circuit, 1984)
Basil Stewart v. Dow Chemical Co.
865 F.2d 103 (Sixth Circuit, 1989)
Wong v. PartyGaming Ltd.
589 F.3d 821 (Sixth Circuit, 2009)
Jacqueline Key v. Shelby County
551 F. App'x 262 (Sixth Circuit, 2014)
Barak v. Zeff
289 F. App'x 907 (Sixth Circuit, 2008)
Henri Solari v. Goodyear Tire & Rubber Co.
654 F. App'x 763 (Sixth Circuit, 2016)
Brandon Hefferan v. Ethicon Endo-Surgery
828 F.3d 488 (Sixth Circuit, 2016)
Paul Jones v. IPX Int'l Equatorial Guinea SA
920 F.3d 1085 (Sixth Circuit, 2019)
Prevent USA Corp. v. Volkswagen AG
17 F.4th 653 (Sixth Circuit, 2021)
Instituto Mexicano del Seguro v. Stryker Corp.
28 F.4th 732 (Sixth Circuit, 2022)
Rustal Trading US, Inc. v. Makki
17 F. App'x 331 (Sixth Circuit, 2001)
Carter v. Paschall Truck Lines, Inc.
364 F. Supp. 3d 732 (W.D. Kentucky, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Fenton Whelan Limited, et al. v. Cleveland Clinic Foundation, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/fenton-whelan-limited-et-al-v-cleveland-clinic-foundation-et-al-ohnd-2025.